Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Net Debt · Q4 FY2025 · quarter ended Dec 2025
Net debt remains negative
Q4 FY2025 net debt was -$7.77M, compared with -$11.76M a year earlier.
Context
- Net debt amounted to 25.7% of total assets at the end of Q4 FY2025, down 36.5 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +34.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (7.77M) USD
- Year-over-year change
- +34.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.77M) | +34.0% |
| FY2024 | 2024-12-31 | (11.76M) | -21.4% |
| FY2023 | 2023-12-31 | (9.69M) | -36.4% |
| FY2022 | 2022-12-31 | (7.1M) | -69.9% |
| FY2021 | 2021-12-31 | (4.18M) | — |
Net Debt vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +34.0% is the 5th highest of 10, against a peer median of +10.7%.
- Net debt amounts to 25.7% of total assets for NNNN, versus a peer median of 23.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.05B USD | -13.0% | -2.7% | 76.2% | |
| Mar 2026 | $161.91M USD | -6.8% | +13.2% | 125.6% | |
| Mar 2026 | $72.8M USD | +65.8% | -35.9% | 6.9% | |
| Mar 2026 | $28M USD | +412.8% | — | 30.0% | |
| Mar 2026 | $21.31M USD | +38.9% | -9.4% | 4.2% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | -$7.77M USD | +34.0% | — | 25.7% |
| Mar 2026 | -$31.41M USD | +47.7% | — | 23.1% | |
| Feb 2026 | -$37.81M USD | +4.9% | — | 14.5% | |
| Mar 2026 | -CA$65.11M CAD | +10.7% | — | 5.0% | |
| Dec 2025 | -$77.77M USD | — | — | 23.2% | |
| Mar 2026 | -$463.18M USD | -103.1% | — | 87.1% | |
| Peer median (excluding NNNN) | — | +10.7% | -6.0% | 23.1% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.